ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Ltd has issued the notice for its 18th Annual General Meeting scheduled for September 24, 2026, alongside the Annual Report for FY 2025-26.
Supriya Lifescience Limited has fixed September 4, 2026, as the record date for its final dividend of Re. 1.00 per share. The dividend awaits AGM approval.
Supriya Lifescience Ltd. shareholders approved the re-appointment of Mr. Balasaheb Sawant as Whole Time Director via postal ballot, as per the voting results.
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience announced financial highlights for Q1 FY27, reporting revenue of Rs. 189.75 crore and profit after tax of Rs. 24.04 crore for the quarter.
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.
Supriya Lifescience Ltd reported revenue from operations of ₹189.7 Cr (+30.7% YoY) and net profit of ₹24 Cr (-31.0% YoY) for Q1 FY27.
Supriya Lifescience Ltd scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Supriya Lifescience Ltd issued a Postal Ballot Notice to shareholders seeking approval for the re-appointment of Mr. Balasaheb Sawant as a Whole Time Director.
Supriya Lifescience Ltd has submitted its quarterly shareholding pattern under SEBI regulations. This filing discloses the stake distribution among promoters and the general public.
Supriya Lifescience disclosed legal proceedings against its GM under NDPS Act. Company states no material financial or operational impact is expected.
Supriya Lifescience achieved record Q4 revenue of ₹277cr, bringing FY26 revenue to ₹828cr. Management maintained its guidance of 20% annual growth and 33-35% EBITDA margins.
Supriya Lifescience Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. The auditor reported no deviations or non-compliances, confirming regulatory adherence.
Supriya Lifescience delivered strong FY26 results with Q4 revenue surging 50% YoY, driven by the anesthetic segment and European market dominance.
Supriya Lifescience reported FY26 revenue of ₹827.87 Crore, up 18.9% YoY. Strong Q4 performance and capacity expansion signal robust growth across key therapeutic segments.
Supriya Lifescience recommended a final dividend of ₹1 per equity share for the 2025-2026 financial year. This board recommendation reflects the company's commitment to returning capital to shareholders.
Supriya Lifescience delivered strong performance in Q4FY26 with 50% YoY revenue growth, driven by expansion in Europe and new product launches in Cardiovascular and ADHD segments.
Supriya Lifescience Ltd reported revenue from operations of ₹276.5 Cr (+50.2% YoY) and net profit of ₹74.2 Cr (+47.2% YoY) for Q4 FY26.
Supriya Lifescience reported a ₹209.12 Crore annual net profit for FY26. The board also recommended a final dividend of ₹1 per equity share.
Supriya Lifescience scheduled a board meeting on May 27, 2026. Directors will consider audited financial results and recommend a potential dividend for fiscal year 2026.
Supriya Lifescience Ltd informed exchanges that it does not qualify as a 'Large Corporate' per SEBI criteria for FY 2026-27. The company reported nil outstanding borrowings and an A+ credit rating from India Ratings. This disclosure confirms compliance with debt-market borrowing framework requirements.
Supriya Lifescience Ltd successfully completed a USFDA inspection at its Lote manufacturing facility. The inspection, conducted in February 2026, concluded with one minor observation and the receipt of an Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI) status. This confirms the facility's compliance with current Good Manufacturing Practice (cGMP) standards.
Supriya Lifescience Limited announced the passing of three special resolutions via postal ballot with requisite majority. Shareholders approved the appointments of Mr. Manish Panchal and Mr. Kothandaraman Hari, and the re-appointment of Dr. Neelam Arora, as Non-Executive Independent Directors for five-year terms.